125 related articles for article (PubMed ID: 32367815)
21. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients.
Wahsh EA; Hussein AK; Gomaa AA; Baraka MA; Al-Deen Abead M
Infect Disord Drug Targets; 2020; 20(1):43-48. PubMed ID: 30009715
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
[TBL] [Abstract][Full Text] [Related]
23. Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics.
Gandhi Y; Eley T; Fura A; Li W; Bertz RJ; Garimella T
Clin Pharmacokinet; 2018 Aug; 57(8):911-928. PubMed ID: 29353349
[TBL] [Abstract][Full Text] [Related]
24. Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo.
Freriksen JJM; Meijerhof M; van Drongelen J; Drenth JPH; Burger DM; Russel FGM; Colbers A; Greupink R
Am J Obstet Gynecol; 2020 Dec; 223(6):941-943. PubMed ID: 32877661
[No Abstract] [Full Text] [Related]
25. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Wyles DL; Ruane PJ; Sulkowski MS; Dieterich D; Luetkemeyer A; Morgan TR; Sherman KE; Dretler R; Fishbein D; Gathe JC; Henn S; Hinestrosa F; Huynh C; McDonald C; Mills A; Overton ET; Ramgopal M; Rashbaum B; Ray G; Scarsella A; Yozviak J; McPhee F; Liu Z; Hughes E; Yin PD; Noviello S; Ackerman P;
N Engl J Med; 2015 Aug; 373(8):714-25. PubMed ID: 26196502
[TBL] [Abstract][Full Text] [Related]
26. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
Simmons B; Wentzel H; Mobarak S; Eslami G; Sadeghi A; Ali Asgari A; Abbaspour Kasgari H; Tirgar Fakheri H; Merat S; Hill A
J Antimicrob Chemother; 2021 Jan; 76(2):286-291. PubMed ID: 33063117
[TBL] [Abstract][Full Text] [Related]
27. Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.
Elsadek HM; Abdelbaser ES; Emara MH; Soliman HH; Farag AA
Eur J Gastroenterol Hepatol; 2020 Aug; 32(8):1046-1053. PubMed ID: 33216478
[TBL] [Abstract][Full Text] [Related]
28. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Manns M; Pol S; Jacobson IM; Marcellin P; Gordon SC; Peng CY; Chang TT; Everson GT; Heo J; Gerken G; Yoffe B; Towner WJ; Bourliere M; Metivier S; Chu CJ; Sievert W; Bronowicki JP; Thabut D; Lee YJ; Kao JH; McPhee F; Kopit J; Mendez P; Linaberry M; Hughes E; Noviello S;
Lancet; 2014 Nov; 384(9954):1597-605. PubMed ID: 25078304
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts.
Rossotti R; Tavelli A; Bonora S; Cingolani A; Lo Caputo S; Saracino A; Soria A; Marinaro L; Uberti-Foppa C; Mussini C; Puoti M; d'Arminio Monforte A
Dig Liver Dis; 2020 Apr; 52(4):447-451. PubMed ID: 31959479
[TBL] [Abstract][Full Text] [Related]
30. Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection.
Cordie A; Elsharkawy A; Abdel Alem S; Meshaal S; El Akel W; Abdellatif Z; Kamal W; Al Askalany M; Kamel S; Abdel Aziz H; Kandeel A; Esmat G
Trans R Soc Trop Med Hyg; 2020 Apr; 114(4):232-240. PubMed ID: 31925434
[TBL] [Abstract][Full Text] [Related]
31. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
[TBL] [Abstract][Full Text] [Related]
32. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C.
Wang HC; Ren YP; Qiu Y; Zheng J; Li GL; Hu CP; Zhou TY; Lu W; Li L
Acta Pharmacol Sin; 2018 Jan; 39(1):140-153. PubMed ID: 28880015
[TBL] [Abstract][Full Text] [Related]
33. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C.
Rivero-Juarez A; Brieva T; Frias M; Rivero A
Expert Opin Drug Metab Toxicol; 2018 Sep; 14(9):901-910. PubMed ID: 30058394
[TBL] [Abstract][Full Text] [Related]
34. Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir.
Nada A; Abbasy M; Sabry A; Abdu Allah AM; Shehab-Eldeen S; Elnaidany N; Elimam H; Mohamed Ibraheem KI; Essa A
Can J Gastroenterol Hepatol; 2020; 2020():1632959. PubMed ID: 32083035
[TBL] [Abstract][Full Text] [Related]
35. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
[TBL] [Abstract][Full Text] [Related]
36. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
[TBL] [Abstract][Full Text] [Related]
37. Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Adkison KK; Jones LS; Lou Y; Gan J; Wilfret DA
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):338-45. PubMed ID: 27129005
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
[TBL] [Abstract][Full Text] [Related]
39. On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.
Kowdley KV; Nelson DR; Lalezari JP; Box T; Gitlin N; Poleynard G; Rabinovitz M; Ravendhran N; Sheikh AM; Siddique A; Bhore R; Noviello S; Rana K
Liver Int; 2016 Nov; 36(11):1611-1618. PubMed ID: 27188960
[TBL] [Abstract][Full Text] [Related]
40. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
